United States Patent 8,628,799 (8,628,799) Combination Tablet With Polyvinyl Alcohol Seal and Saxagliptin: Scope, Claim Coverage, and US Patent Landscape

US Patent 8,628,799 is directed to a coated combination saxagliptin tablet built as a multi-layer coating system: an inner seal coating layer (polyvinyl alcohol-based), a drug-containing second coating layer (saxagliptin plus polyvinyl alcohol-based polymer), and an outer protective coating layer (polyvinyl alcohol-based). Independent claim 1 also includes the key limitation that the “drug tablet is other than saxagliptin,” which narrows the claim to combination products where saxagliptin is in the coating layer rather than the tablet core. Dependent claims then specify composition ranges, salt form, and excipient makeup (PEG, talc, titanium dioxide).

Because the claim text you provided does not include the patent’s specification, priority dates, or the prosecution history, this analysis focuses strictly on claim scope implied by the claim language and on how that claim architecture typically shapes US freedom-to-operate risk for saxagliptin combinations and coated dosage forms.

What patents protect the coated saxagliptin tablet with polyvinyl alcohol inner seal layers?

Core invention claim structure (Claim 1)

Claim 1 recites a “combination formulation” with four functional components in one product:

A drug tablet (tablet core)
Inner seal coating layer on the drug tablet
- Polymer: polyvinyl alcohol (PVA)
- Amount: about 1 mg to 100 mg of “coating polymer formulation” comprising PVA
Second coating layer on the inner seal coating layer
- Drug: saxagliptin or a pharmaceutically acceptable salt
- Polymer: PVA-based “coating polymer formulation”
- Amounts: about 0.2 mg to 140 mg saxagliptin/salt and about 2 mg to 140 mg PVA polymer formulation
Outer protective coating layer on the second coating layer
- Polymer: PVA-based
- Amount: about 1 mg to 100 mg of PVA polymer formulation

Tablet core exclusion: “wherein the drug tablet is other than saxagliptin or a pharmaceutically acceptable salt thereof.”
This is the single most important scope limiter: it excludes products where saxagliptin is the uncoated tablet active.

Quantitative claim boundaries that drive design-around

Claim 1 sets broad absolute-mass ranges for each layer. Dependent claims then carve narrower compositions and “consists essentially of” embodiments.

Key quantitative anchors:

Inner seal coating layer polymer (PVA formulation): 1 to 100 mg
Second coating layer saxagliptin/salt: 0.2 to 140 mg
Second coating layer PVA formulation: 2 to 140 mg
Outer protective coating layer polymer (PVA formulation): 1 to 100 mg

Even with broad ranges, a challenger can often seek escape routes via:

Different polymer identity (replace PVA with another film former; avoid “comprising a coating polymer formulation comprising polyvinyl alcohol”)
Different multi-layer architecture (fewer layers or elimination of the inner seal and/or outer protective layer)
Different placement of saxagliptin (saxagliptin in tablet core rather than in the second coating layer)
Mass out-of-range or salt/freebase choices that avoid dependent claims (though Claim 1 itself covers both free base and salts unless you focus on dependent limitations)

Salt form sub-scope (Claim 4)

Claim 4 limits saxagliptin to hydrochloride salt for that dependent claim. If a product uses saxagliptin free base or another pharmaceutically acceptable salt, it can avoid Claim 4 while still potentially meeting Claim 1.

PEG, talc, and titanium dioxide sub-scope (Claims 5–10)

Claims 5–10 add specific excipient compositions:

Inner seal layer may further include polyethylene glycol (Claim 5)
Inner seal example composition (Claim 6):
- about 40% PVA
- about 20% PEG
- about 15% talc
- about 25% titanium dioxide
Second and outer layers include analogous optional components (Claims 7–10)

These dependent claims are strongest when accused products match the exact formulation profile, not just PVA/PEG.

“Consists essentially of” narrowing with “about” ranges (Claim 11)

Claim 11 is a second major scope-control mechanism. It states:

Inner seal layer: consists essentially of PVA polymer formulation amount 2 mg to 6 mg
Second coating layer: consists essentially of
- saxagliptin (free base or HCl) 0.5 mg to 140 mg
- PVA polymer formulation 2 mg to 100 mg
Outer protective layer: consists essentially of PVA polymer formulation amount 2 mg to 10 mg

“Consists essentially of” is usually interpreted to allow impurities or minor components that do not materially affect basic and novel characteristics, while excluding added excipients that materially change composition. That can matter if a competitor uses talc or titanium dioxide or extra plasticizers not contemplated as “essential” to the claimed film-forming function.

How broad are the claims of US 8,628,799 for coated saxagliptin combinations vs narrower dependent formulations?

Claim 1 breadth assessment

Claim 1 is broad in these respects:

Accepts “polyvinyl alcohol” as part of a polymer formulation in each of three layers.
Accepts saxagliptin as free base or pharmaceutically acceptable salt.
Uses wide absolute-mass ranges for each coating layer component.

Claim 1 is narrow in these respects:

Saxagliptin must be in the second coating layer.
The tablet core must be other than saxagliptin or its salt.

Dependent claims function as “claim ladder”

Claims 2 and 3 narrow the second coating layer by weight % and minimum amounts.
Claims 5–10 narrow each layer’s excipient set (PEG, talc, titanium dioxide) and specify exemplar percentages.
Claim 4 narrows salt form to HCl.
Claim 11 narrows to “consists essentially of” and specific coating-layer mass bands.

From an infringement and validity perspective, Claim 1 establishes the platform. Dependent claims constrain that platform to specific compositions and “essentially of” formulations.

Which products could infringe US 8,628,799: saxagliptin in coatings on non-saxagliptin cores?

Product architecture that matches the claim

A product is more likely to fall within the literal scope if it has:

A tablet core containing some other drug (not saxagliptin)
An applied inner seal coat containing a PVA-based polymer formulation in the specified mg range
A drug-containing coating layer over that seal where saxagliptin is added in the coating (not as core API)
An outer protective coat with PVA polymer in mg range

Key non-infringing architectures

Common design-around patterns that typically avoid Claim 1:

Single coat (no inner seal and outer protective layer)
No PVA polymer formulation (use different film former as the coating polymer base)
Saxagliptin is the tablet core API rather than only in the coating layer (fails “drug tablet is other than saxagliptin”)
Saxagliptin in an uncoated core + coating layers without saxagliptin (moves saxagliptin out of “second coating layer” requirement)

What patent claims in US 8,628,799 are most vulnerable to design-around? (Polymer identity and layer placement)

Polymer substitution risk

Because every layer described uses “coating polymer formulation comprising polyvinyl alcohol,” a competitor can often reduce risk by selecting a different primary film former (or a system where PVA is absent as a meaningful component). If the competitor’s coat is a polymer blend without PVA, it avoids the central claim element.

Layer-structure substitution risk

If the competitor eliminates one of the three layers as claimed (inner seal or outer protective) or merges layers into a different coating system not meeting the claim’s distinct-layer structure, literal infringement risk can drop sharply.

Saxagliptin placement risk

The “drug tablet is other than saxagliptin” language makes it less likely that products where saxagliptin is an internal core component can match Claim 1. If saxagliptin is in the core and another drug is coated, that can invert the architecture.

How does the “consists essentially of” language affect infringement for talc and titanium dioxide embodiments?

Claim 11 can be read as:

restricting additional excipients in each “consists essentially of” layer, especially if talc or titanium dioxide are present in an amount that materially affects film characteristics.

Claims 6 and 8–10 include talc and titanium dioxide in exemplar compositions. If a competitor uses those excipients, infringement exposure rises for those dependent claims, but Claim 11 may remain contested depending on whether those excipients are considered to be within the “consists essentially of” boundaries.

What US patent estate surrounds 8,628,799: formulation patents, coating methods, and saxagliptin combination IP?

Landscape logic based on claim theme

Even without the patent’s full family details, the claim theme indicates typical surrounding US IP categories for a saxagliptin combination tablet:

Film coating compositions using PVA and related polymer blends (inner seal, drug-containing coat, outer protective coat)
Layered tablet coating architectures (multi-layer coating systems to control stability or taste)
Salt form and dose-layer stability claims (HCl vs free base behavior in coating films)
Method-of-manufacture patents for applying layered coats and achieving specified film thickness and composition ranges

Likely claim adjacency

Given the quantification in mg ranges and weight % ranges, practitioners often file parallel claims covering:

specific coating thickness/weight targets
specific polymer blends and plasticizers (PEG)
specific pigments/anti-adherents (talc, TiO2)
alternative salt forms
coated-bead or granule precursor intermediates

For enforcement, Claim 1 is the broadest “architecture + polymer identity + placement” hook. Dependent claims strengthen infringement when product formulation matches those example compositions.

When does US 8,628,799 lose enforceability: expiration timing and exclusivity impact?

A complete enforceability timeline requires publication, priority, patent term adjustment, and any terminal disclaimer data not provided in the prompt. Since those facts are not included, no accurate US expiration date or litigation gating can be computed here.

What generic entry risks exist for saxagliptin combination tablets using PVA multilayer coatings?

Risk profile for ANDA filers

Generic risk concentrates when:

the generic’s final dosage form includes the same layered coating architecture and
the coatings use PVA-based polymer formulations in the claimed mg ranges and
saxagliptin is placed in the same second coating layer over an inner seal on a non-saxagliptin core.

If the ANDA relies on a different coating system (different polymers, different number of layers, or saxagliptin positioned in a different structural part of the tablet), the specific claim architecture in 8,628,799 may not be met.

Risk profile for Paragraph IV litigation

If 8,628,799 is listed for a branded product in the FDA Orange Book, Paragraph IV challenges typically target either:

non-infringement based on coating differences (polymer identity, layer count, placement), or
invalidity based on anticipation/obviousness of multi-layer PVA coating systems for other APIs or saxagliptin formulations.

The strongest non-infringement argument usually ties to one of three claim anchors:

lack of PVA,
different layered structure,
saxagliptin not in the second coating layer or core is saxagliptin.

How does US 8,628,799 compare with other layered coating approaches for DPP-4 inhibitors?

Comparison by claim elements

Many DPP-4 inhibitor formulation patents focus on drug-core formulations (immediate/extended release matrices).
This patent’s distinguishing claim element is the saxagliptin-in-coating-layer placement on a non-saxagliptin tablet core, combined with PVA-based inner seal and outer protective layers.

That makes the claimed invention more like a dosage-form engineering patent than a typical simple composition patent.

What manufacturing/IP barriers does 8,628,799 create for contract manufacturers?

Process sensitivity inferred from claim structure

Even though no method-of-manufacture claims are provided, layered coating claims typically drive practical barriers:

controlling coating weights to hit mg ranges (1 to 100 mg for each PVA layer in Claim 1; 2 to 6 mg and 2 to 10 mg in Claim 11)
ensuring layered deposition so saxagliptin is in the second layer and not migrating into seal or outer layer formulations
maintaining film composition within polymer and excipient profiles, especially for talc and TiO2 embodiments

Key claim-by-claim scope map for US 8,628,799

Claim	Main additional limitation	Practical infringement trigger
1	Multi-layer coated combination: inner seal PVA coat (1–100 mg) + second coat with saxagliptin (0.2–140 mg) and PVA (2–140 mg) + outer protective PVA coat (1–100 mg); core tablet is not saxagliptin/salt	Tablet architecture with saxagliptin only in second coating layer over PVA inner/outer films
2	Second coat wt%: 0.1–70% saxagliptin; 30–99.5% PVA polymer formulation	Exact dose-layer blend ratios
3	At least about 2 mg PVA polymer for a 200 mg drug tablet; saxagliptin at least 0.2 mg	Minimum layer loading thresholds tied to tablet size
4	Saxagliptin is HCl	Formulation salt form
5	Inner seal includes PEG	PEG presence in inner seal layer
6	Inner seal example: 40% PVA, 20% PEG, 15% talc, 25% TiO2	Matches exemplar excipient profile
7	Second coat PVA polymer further includes PEG	PEG presence in drug-containing layer
8	Second coat example: 40% PVA, 20% PEG, 15% talc, 25% TiO2	Matches exemplar excipient profile
9	Outer protective coat further includes PEG	PEG presence in outer layer
10	Outer coat example: 40% PVA, 20% PEG, 15% talc, 25% TiO2	Matches exemplar excipient profile
11	“Consists essentially of” each layer with tighter mg bands (inner seal 2–6 mg; second coat saxagliptin 0.5–140 mg and PVA 2–100 mg; outer 2–10 mg)	Very specific “essentially of” composition and layer weight loading

Key Takeaways

Claim 1 is a structural architecture claim: saxagliptin must be in a second coating layer positioned over a PVA-based inner seal and covered by a PVA-based outer protective layer, with the tablet core being non-saxagliptin.
Dependent claims mainly add composition-specific constraints: saxagliptin HCl, PEG inclusion, and exemplar PVA/PEG/talc/TiO2 percentages, plus a tighter “consists essentially of” embodiment with specific coating mg ranges.
From a generic or challenger standpoint, the highest-probability design-around hooks are: remove PVA, change layered structure, or move saxagliptin out of the claimed second coating layer placement.

FAQs

Can a product infringe Claim 1 if saxagliptin is in the tablet core rather than the second coating layer?
If saxagliptin is in the core, it generally conflicts with the claim requirement that the “drug tablet is other than saxagliptin,” and with the requirement that saxagliptin is present in the second coating layer.
Does using saxagliptin free base avoid the patent?
It may avoid dependent Claim 4 (HCl-specific) but does not avoid Claim 1, which covers saxagliptin or pharmaceutically acceptable salts.
Are talc and titanium dioxide mandatory to practice the broadest scope?
No. Talc and titanium dioxide appear in dependent exemplar claims (Claims 6 and 8–10). Claim 1 only requires PVA-based polymer formulations in each layer.
How do “about” ranges affect infringement analysis for coated layer weights?
“About” makes exact matching less rigid than a fixed number, increasing risk for close-range products, but it does not eliminate non-infringement arguments based on clearly outside claimed bounds.
What is the most practical way to reduce litigation exposure under this patent theme?
Change one of the claim’s anchors: coating polymer identity (avoid PVA), remove or merge claimed layers so the architecture is not met, or alter where saxagliptin is located structurally so it is not in the claimed second coating layer on a non-saxagliptin core.

References

United States Patent 8,628,799 (claims provided in prompt).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	049062	⤷ Start Trial
Argentina	099567	⤷ Start Trial
Australia	2005249467	⤷ Start Trial
Brazil	PI0510419	⤷ Start Trial
Canada	2568391	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,628,799

Summary for Patent: 8,628,799